Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration
JAMA · 2023
DOI: 10.1001/jama.2023.3494 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, 2023. Verfasst von Boris Mraovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, University of Missouri School of Medicine, Columbia. Hauptthemen laut MEDLINE: Analgesics, Opioid, Neuromuscular Blocking Agents, Rapid Sequence Induction and Intubation, Remifentanil. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor Although we agree with the conclusion that use of remifentanil is inferior to neuromuscular blocking agents, we have some concerns about the recent study1 that examined whether patients at risk of aspiration could safely undergo intubation without use of neuromuscular blocking agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, University of Missouri School of Medicine, Columbia.
- Department of Anaesthesiology, Reanimatology, and Intensive Care Medicine, Zadar General Hospital, Zadar, Croatia.
Zitieren
APA
Mraovic, B., Timko, N. J., & Simurina, T. (2023). Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration. JAMA. https://doi.org/10.1001/jama.2023.3494
Vancouver
Mraovic B, Timko NJ, Simurina T. Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration. JAMA. 2023. doi:10.1001/jama.2023.3494
BibTeX
@article{Mraovic2023,
author = {Mraovic, Boris and Timko, Noah J and Simurina, Tatjana},
title = {Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.3494}
}
EUVIMED